Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 127.99B |
| Revenue (ttm) | 10.34B |
| Net Income (ttm) | -489.90M |
| Shares Out | 258.10M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | 28.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,808,863 |
| Open | 495.67 |
| Previous Close | 493.35 |
| Day's Range | 492.29 - 500.21 |
| 52-Week Range | 340.83 - 510.64 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 495.82 (-0.01%) |
| Earnings Date | Aug 1, 2024 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl... [Read more]
Financial Performance
In 2023, VRTX's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $495.82, which is a decrease of -0.01% from the latest price.
News
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Offic...
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access t...
Investing in biotech outside of weight-loss drugs
GLP-1 weight-loss drugs have pushed the biotech sector to new heights as demand steadily increases. But despite the drugs' popularity, there are other investment opportunities within the biotech secto...
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis t...
Vertex Pharmaceuticals, Inc. (VRTX) Q2 2024 Earnings Call Transcript
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Ch...
Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments
Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments.
Vertex Reports Second Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product r...
Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration
LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for ...
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--A Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody Conjuga...
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and ...
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigati...
Vertex to Announce Second Quarter 2024 Financial Results on August 1
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The com...
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differenti...
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
The Investment Committee share their top stocks to watch for the second half.
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people wit...
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants David Altshuler - Chief Scientific Officer Char...
Vertex Shares Rising on Expanded Therapy Offerings
Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.
Vertex Pharmaceuticals Incorporated (VRTX) The 44th Annual William Blair Growth Stock Conference
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) The 44th Annual William Blair Growth Stock Conference June 4, 2024 5:00 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer Confe...
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union an...
Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's inno...